Alector Inc logo

ALEC - Alector Inc Share Price

$16.59 0.4  2.3%

Last Trade - 22/01/21

Mid Cap
Market Cap £935.4m
Enterprise Value £599.2m
Revenue £16.2m
Position in Universe 2482nd / 6626
Unlock ALEC Revenue
Relative Strength (%)
1m -7.01%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.42 3.74 27.7 21.2 24.6 35.0 +270.9%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AlectorInc revenues increased 7% to $16.2M. Net loss increased 84%to $138M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Research anddevelopment - Balancing increase of 47% to $101.9M(expense), General and administrative - Balancing increasefrom $17M to $35.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALEC
Graphical History


ALEC Revenue Unlock ALEC Revenue

Net Income

ALEC Net Income Unlock ALEC Revenue

Normalised EPS

ALEC Normalised EPS Unlock ALEC Revenue

PE Ratio Range

ALEC PE Ratio Range Unlock ALEC Revenue

Dividend Yield Range

ALEC Dividend Yield Range Unlock ALEC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALEC EPS Forecasts Unlock ALEC Revenue
Profile Summary

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated September 19, 2017
Public Since February 7, 2019
No. of Shareholders: 27
No. of Employees: 162
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 79,242,709
Free Float (0.0%)
Eligible for
ALEC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALEC
Upcoming Events for ALEC
Monday 22nd March, 2021 Estimate
Q4 2020 Alector Inc Earnings Release
Tuesday 11th May, 2021 Estimate
Alector Inc Annual Shareholders Meeting
Tuesday 11th May, 2021 Estimate
Q1 2021 Alector Inc Earnings Release
Frequently Asked Questions for Alector Inc
What is the Alector Inc share price?

As of 22/01/21, shares in Alector Inc are trading at $16.59, giving the company a market capitalisation of £935.4m. This share price information is delayed by 15 minutes.

How has the Alector Inc share price performed this year?

Shares in Alector Inc are currently trading at $16.59 and the price has moved by -29.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alector Inc price has moved by -38.97% over the past year.

What are the analyst and broker recommendations for Alector Inc?

Of the analysts with advisory recommendations for Alector Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alector Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Alector Inc next release its financial results?

Alector Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Alector Inc dividend yield?

Alector Inc does not currently pay a dividend.

Does Alector Inc pay a dividend?

Alector Inc does not currently pay a dividend.

When does Alector Inc next pay dividends?

Alector Inc does not currently pay a dividend.

How do I buy Alector Inc shares?

To buy shares in Alector Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alector Inc?

Shares in Alector Inc are currently trading at $16.59, giving the company a market capitalisation of £935.4m.

Where are Alector Inc shares listed? Where are Alector Inc shares listed?

Here are the trading details for Alector Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALEC
What kind of share is Alector Inc?

Based on an overall assessment of its quality, value and momentum, Alector Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alector Inc share price forecast 2021?

Shares in Alector Inc are currently priced at $16.59. At that level they are trading at 98.21% discount to the analyst consensus target price of 0.00.

Analysts covering Alector Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.477 for the next financial year.

How can I tell whether the Alector Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alector Inc. Over the past six months, the relative strength of its shares against the market has been -38.54%. At the current price of $16.59, shares in Alector Inc are trading at -12.04% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alector Inc PE Ratio?

We were not able to find PE ratio data for Alector Inc.

Who are the key directors of Alector Inc?

Alector Inc's management team is headed by:

Arnon Rosenthal - CEO
David Wehner - IND
Terry McGuire - IND
Tillman Gerngross - CHM
Richard Scheller - IND
Louis Lavigne - LED
Robert Paul - OTH
Robert King - OTH
Sabah Oney - OTH
Calvin Yu - VFN
Shehnaaz Suliman - PRE
Paula Hammond - IND
Who are the major shareholders of Alector Inc?

Here are the top five shareholders of Alector Inc based on the size of their shareholding:

Polaris Venture Partners Venture Capital
Percentage owned: 16.23% (12.9m shares)
Rosenthal (Arnon Ph.D.) Individual Investor
Percentage owned: 7.64% (6.06m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.16% (4.88m shares)
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund
Percentage owned: 6.14% (4.86m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.98% (3.95m shares)
Similar to ALEC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.